Questex's Fierce Pharma Announces the 2024 Fierce Pharma Marketing Awards Finalists [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Questex's Fierce Pharma today announces the finalists for the Fierce Pharma Marketing Awards which honor leadership, vision, innovation and strategic accomplishments within the pharma marketing and advertising community. The Awards program received hundreds of submissions in all 15 categories. The finalists were chosen based on creativity, strategy, audience impact, social good, innovation and effectiveness. “Pharmaceutical marketing plays an important role in conveying a brand to healthcare professionals, patients, and stakeholders,” said Rebecca Willumson, SVP & Publisher of Fierce Pharma. “We are extremely impressed by the innovation and creativity of all of the submissions to our program this year. We congratulate the finalists on their accomplishments.” The 2024 finalists: NEW: Agency of the Year Believe Limited Initiative minds + assembly PROPELLER Real Chemistry Digital Campaign – Non-Social Media AbelsonTaylor
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Finance]Yahoo! Finance
- Disney, DirecTV fail to reach distribution deal [Yahoo! Finance Canada]Yahoo! Finance Canada
- Why Neurocrine Biosciences Stock Was Tumbling This Week [Yahoo! Finance]Yahoo! Finance
- Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Cantor Fitzgerald from $170.00 to $155.00. They now have an "overweight" rating on the stock.MarketBeat
NBIX
Earnings
- 8/1/24 - Beat
NBIX
Sec Filings
- 8/28/24 - Form 8-K
- 8/16/24 - Form 4
- 8/15/24 - Form 4
- NBIX's page on the SEC website